Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

8.5K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.5K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

140
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
140
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.3K
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

1.0K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.0K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

456
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
456
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

272
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
272

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Loop Gain in Obstructive Sleep Apnea: From Physiological Endotype to Clinical Translation.

Nature and science of sleep·2026
Same author

Regulatory insights underlying apple to cold stress.

Horticulture research·2026
Same author

The HFpEF-ABA score predicts adverse cardiac remodelling and incident heart failure: a UK biobank study.

ESC heart failure·2026
Same author

Latent profiles of health insurance literacy, numeracy and supplementary voluntary health insurance enrollment.

Health economics review·2026
Same author

Research on Pathological Voice Recognition Based on XGBoost.

Journal of visualized experiments : JoVE·2026
Same author

High-Entropy Gradient-Like Design Enables 4.7 V High-Stability LiCoO<sub>2</sub> for Lithium-Ion Battery.

Small (Weinheim an der Bergstrasse, Germany)·2026

Related Experiment Video

Updated: May 16, 2025

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

472

Isoquercitrin Alleviates Diabetic Nephropathy by Inhibiting STAT3 Phosphorylation and Dimerization.

Chen Xuan1,2, Donghui Chen2,3, Shuangna Zhang2

  • 1School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|April 4, 2025
PubMed
Summary

Isoquercitrin effectively treats diabetic nephropathy by inhibiting signal transducer and activator of transcription 3 (STAT3). This natural compound, delivered via a novel nanocarrier, reduces kidney inflammation and fibrosis, offering a promising new therapy.

Keywords:
Iso@PEG‐GKSH2 domainSTAT3diabetic nephropathydimerizationisoquercitrinphosphorylation

More Related Videos

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
14:18

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

1.6K
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

298

Related Experiment Videos

Last Updated: May 16, 2025

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

472
Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
14:18

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

1.6K
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

298

Area of Science:

  • Biochemistry
  • Pharmacology
  • Nephrology

Background:

  • Diabetic nephropathy (DN) presents a significant health challenge, with signal transducer and activator of transcription 3 (STAT3) emerging as a key therapeutic target.
  • Isoquercitrin, a natural compound, is recognized for its potential to inhibit STAT3, but its precise mechanism in DN remains largely unexplored.

Purpose of the Study:

  • To elucidate the therapeutic mechanism of isoquercitrin in diabetic nephropathy by investigating its interaction with STAT3.
  • To develop and evaluate a novel kidney-targeted nanocarrier for enhanced delivery of isoquercitrin in DN treatment.

Main Methods:

  • Investigated the effect of isoquercitrin on renal inflammation and fibrosis in a mouse model of diabetic nephropathy.
  • Utilized biophysical techniques to confirm the direct binding of isoquercitrin to STAT3, specifically within the SH2 domain.
  • Developed and characterized a kidney-targeted nanocarrier (Iso@PEG-GK) for isoquercitrin delivery.

Main Results:

  • Isoquercitrin significantly reduced inflammation and fibrosis in mice with diabetic nephropathy by inhibiting STAT3 activity.
  • Confirmed direct, noncovalent binding of isoquercitrin to the Ser668-Gln635-Gln633 region of the STAT3 SH2 domain, obstructing phosphorylation and dimerization.
  • The Iso@PEG-GK nanocarrier demonstrated enhanced absorption and improved renal distribution of isoquercitrin, leading to superior therapeutic outcomes.

Conclusions:

  • Isoquercitrin exerts a protective effect against diabetic nephropathy through direct inhibition of STAT3 signaling.
  • The development of a kidney-targeted nanocarrier enhances the therapeutic potential of isoquercitrin for diabetic nephropathy.
  • Isoquercitrin represents a promising novel therapeutic agent for managing diabetic nephropathy.